RADNOR, Pa. - Mineralys Therapeutics , Inc. (NASDAQ:MLYS), a biopharmaceutical company specializing in the development of treatments for cardiovascular and kidney diseases, has announced the ...

The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

Drug-resistant infections occur when pathogens change in ways that render antimicrobial drugs ineffective. As a result, the pathogens survive and continue to spread. When infections are treatable with ...

Background Primary prevention strategies for cardiovascular disease (CVD) conventionally rely on 10-year risk estimates of ...